TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2843-2851

  Cipollini, Monica ^a   Pastor, Susana ^b,c   Gemignani, Federica ^a   Castell, Juan ^d   Garritano, Sonia ^a   Bonotti, Alessandra ^e   Biarnés, Josefina ^f   Figlioli, Gisella ^a   Romei, Cristina ^a   Marcos, Ricard ^b,c   Cristaudo, Alfonso ^e   Elisei, Rossella ^a   Landi, Stefano ^a   Velázquez, Antonia ^b,c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

^f HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

association; cancer susceptibility; thyroid cancer risk; TPO gene

Indexed keywords

DNA; THYROID PEROXIDASE;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; ETHNIC DIFFERENCE; ETHNIC GROUP; EUROPEAN; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; ITALIAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SPANISH; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TPO GENE;

ASSOCIATION; CANCER SUSCEPTIBILITY; THYROID CANCER RISK; TPO GENE;

FEMALE; GENOTYPE; HUMANS; IODIDE PEROXIDASE; ITALY; LOGISTIC MODELS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SPAIN; THYROID NEOPLASMS;

EID: 84885650888     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28317     Document Type: Article

References (46)

1. Kondo T, Ezzat S, Asa SL,. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306.
2. Chen AY, Jemal A, Ward EM,. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115: 3801-7.
3. Aschebrook-Kilfoy B, Ward MH, Sabra MM, et al. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011; 21: 125-34.
4. Hemminki K, Li X,. Familial risk of cancer by site and histopathology. Int J Cancer 2003; 103: 105-9.
5. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004; 1: e65.
6. Sturgis EM, Li G,. Molecular epidemiology of papillary thyroid cancer: in search of common genetic associations. Thyroid 2009; 19: 1031-4.
7. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 2009; 41: 460-4.
8. Gudmundsson J, Sulem P, Gudbjartsson DF, et al,. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet 2012; 44: 319-22.
9. Takahashi M, Saenko VA, Rogounovitch TI, et al,. The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in chernobyl. Hum Mol Genet 2010; 19: 2516-23.
10. Baida A, Akdi M, Gonzalez-Flores E, et al. Strong association of chromosome 1p12 loci with thyroid cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2008; 17: 1499-504.
11. Ho T, Li G, Lu J, et al. Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. Thyroid 2009; 19: 129-35.
12. Landa I, Ruiz-Llorente S, Montero-Conde C, et al,. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet 2009; 5: e1000637.
13. Akdi A, Gimenez EM, Garcia-Quispes W, et al. WDR3 gene haplotype is associated with thyroid cancer risk in a Spanish population. Thyroid 2010; 20: 803-9.
14. Cancemi L, Romei C, Bertocchi S, et al. Evidences that the polymorphism pro-282-ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. Int J Cancer 2011; 129: 2816-24.
15. Garcia-Quispes WA, Perez-Machado G, Sandoval B, et al. Are thyroid cancer patients sensitive to ionising radiation? Int J Radiat Biol 2011; 87: 932-5.
16. Matakidou A, Hamel N, Popat S, et al. Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. Carcinogenesis 2004; 25: 369-73.
17. Baida A, Farrington SM, Galofre P, et al. Thyroid cancer susceptibility and THRA1 and BAT-40 repeats polymorphisms. Cancer Epidemiol Biomarkers Prev 2005; 14: 638-42.
18. Rebai M, Kallel I, Charfeddine S, et al. Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk. J Recept Signal Transduct Res 2009; 29: 113-8.
19. Lonn S, Bhatti P, Alexander BH, et al. Papillary thyroid cancer and polymorphic variants in TSHR- and RET-related genes: a nested case-control study within a cohort of U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 2007; 16: 174-7.
20. Akdi A, Perez G, Pastor S, et al. Common variants of the thyroglobulin gene are associated with differentiated thyroid cancer risk. Thyroid 2011; 21: 519-25.
21. Pastor S, Akdi A, González E, et al. Common genetic variants in pituitary-thyroid axis genes and the risk of differentiated thyroid cancer. Endocr Connect 2012; 1: 68-77.
22. Nunez J, Pommier J,. Formation of thyroid hormones. Vitam Horm 1982; 39: 175-229.
23. Ris-Stalpers C, Bikker H,. Genetics and phenomics of hypothyroidism and goiter due to TPO mutations. Mol Cell Endocrinol 2010; 322: 38-43.
24. Avbelj M, Tahirovic H, Debeljak M, et al. High prevalence of thyroid peroxidase gene mutations in patients with thyroid dyshormonogenesis. Eur J Endocrinol 2007; 156: 511-9.
25. Belforte FS, Miras MB, Olcese MC, et al. Congenital goitrous hypothyroidism: mutation analysis in the thyroid peroxidase gene. Clin Endocrinol 2012; 76: 568-76.
26. Yashiro T, Ito K, Akiba M, et al. Papillary carcinoma of the thyroid arising from dyshormonogenetic goiter. Endocrinol Jpn 1987; 34: 955-64.
27. Medeiros-Neto G, Gil-Da-Costa MJ, Santos CL, et al. Metastatic thyroid carcinoma arising from congenital goiter due to mutation in the thyroperoxidase gene. J Clin Endocrinol Metab 1998; 83: 4162-6.
28. Chertok Shacham E, Ishay A, Irit E, et al. Minimally invasive follicular thyroid carcinoma developed in dyshormonogenetic multinodular goiter due to thyroid peroxidase gene mutation. Thyroid 2012; 22: 542-6.
29. Gerard AC, Daumerie C, Mestdagh C, et al. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab 2003; 88: 4977-83.
30. Di Cristofaro J, Silvy M, Lanteaume A, et al. Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. Endocr Relat Cancer 2006; 13: 485-95.
31. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005; 24: 6646-56.
32. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-3.
33. Romei C, Ciampi R, Faviana P, et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008; 15: 511-20.
34. Wang M, Marin A,. Characterization and prediction of alternative splice sites. Gene 2006; 366: 219-27.
35. Reese MG, Eeckman FH, Kulp D, et al. Improved splice site detection in genie. J Comput Biol 1997; 4: 311-23.
36. Mathe E, Olivier M, Kato S, et al. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 2006; 34: 1317-25.
37. Hothorn LA, Hothorn T,. Order-restricted scores test for the evaluation of population-based case-control studies when the genetic model is unknown. Biom J 2009; 51: 659-69.
38. Armitage P,. Test for linear trends in proportions and frequencies. Biometrics 1955; 11: 375-86.
39. Dupont WD, Plummer WD Jr., Power and samples size calculations. A review and computer program. Control Clin Trials 1990; 11: 116-28.
40. Kallel R, Belguith-Maalej S, Akdi A, et al. Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: new insight on the role of FOXE1 in thyroid carcinoma. Cancer Biomark 2010-2011; 8: 43-51.
41. Matsuse M, Takahashi M, Mitsutake N, et al. The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J Med Genet 2011; 48: 645-8.
42. Bullock M, Duncan EL, O'Neill C, et al. Association of FOXE1 polyalanine repeat region with papillary thyroid cancer. J Clin Endocrinol Metab 2012; 97: E1814-9.
43. Tomaz RA, Sousa I, Silva JG, et al. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. Clin Endocrinol 2012; 77: 926-33.
44. Ruf J, Carayon P,. Structural and functional aspects of thyroid peroxidase. Arch Biochem Biophys 2006; 445: 269-77.
45. Johnston LE, Tran Cao HS, Chang DC, et al. Sociodemographic predictors of survival in differentiated thyroid cancer: Results from the SEER database. ISRN Endocrinol 2012; 2012: 384707.
46. Hemminki K, Eng C, Chen B,. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 5747-53.